Cargando…

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients

Multiple myeloma survival has significantly improved in recent years, due to novel agents that are available for treatment. The anti-CD38 monoclonal antibody Daratumumab is particularly efficient for patients with relapse/refractory disease, and many studies have shown its unprecedented efficacy als...

Descripción completa

Detalles Bibliográficos
Autores principales: Gozzetti, Alessandro, Bacchiarri, Francesca, Sammartano, Vincenzo, Defina, Marzia, Sicuranza, Anna, Mecacci, Bianca, Zappone, Elisabetta, Cencini, Emanuele, Fabbri, Alberto, Raspadori, Donatella, Bocchia, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783633/
https://www.ncbi.nlm.nih.gov/pubmed/33415072
http://dx.doi.org/10.3389/fonc.2020.570187
_version_ 1783632149330526208
author Gozzetti, Alessandro
Bacchiarri, Francesca
Sammartano, Vincenzo
Defina, Marzia
Sicuranza, Anna
Mecacci, Bianca
Zappone, Elisabetta
Cencini, Emanuele
Fabbri, Alberto
Raspadori, Donatella
Bocchia, Monica
author_facet Gozzetti, Alessandro
Bacchiarri, Francesca
Sammartano, Vincenzo
Defina, Marzia
Sicuranza, Anna
Mecacci, Bianca
Zappone, Elisabetta
Cencini, Emanuele
Fabbri, Alberto
Raspadori, Donatella
Bocchia, Monica
author_sort Gozzetti, Alessandro
collection PubMed
description Multiple myeloma survival has significantly improved in recent years, due to novel agents that are available for treatment. The anti-CD38 monoclonal antibody Daratumumab is particularly efficient for patients with relapse/refractory disease, and many studies have shown its unprecedented efficacy also as a first treatment. However, to avoid the incidence of infusion reactions, long infusion schedules of 8 h at first dose and 4 h in the following doses are required, which can reduce the compliance of patients and health care professionals. A reduced infusion time of 90 min has been reported previously, but data are missing on the prolonged safety of this over time as well as the efficacy of this approach. In this work, we investigate the safety of 484 rapid Daratumumab infusions given early after the second dose over a 22 months period in 39 myeloma patients.
format Online
Article
Text
id pubmed-7783633
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77836332021-01-06 Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients Gozzetti, Alessandro Bacchiarri, Francesca Sammartano, Vincenzo Defina, Marzia Sicuranza, Anna Mecacci, Bianca Zappone, Elisabetta Cencini, Emanuele Fabbri, Alberto Raspadori, Donatella Bocchia, Monica Front Oncol Oncology Multiple myeloma survival has significantly improved in recent years, due to novel agents that are available for treatment. The anti-CD38 monoclonal antibody Daratumumab is particularly efficient for patients with relapse/refractory disease, and many studies have shown its unprecedented efficacy also as a first treatment. However, to avoid the incidence of infusion reactions, long infusion schedules of 8 h at first dose and 4 h in the following doses are required, which can reduce the compliance of patients and health care professionals. A reduced infusion time of 90 min has been reported previously, but data are missing on the prolonged safety of this over time as well as the efficacy of this approach. In this work, we investigate the safety of 484 rapid Daratumumab infusions given early after the second dose over a 22 months period in 39 myeloma patients. Frontiers Media S.A. 2020-12-21 /pmc/articles/PMC7783633/ /pubmed/33415072 http://dx.doi.org/10.3389/fonc.2020.570187 Text en Copyright © 2020 Gozzetti, Bacchiarri, Sammartano, Defina, Sicuranza, Mecacci, Zappone, Cencini, Fabbri, Raspadori and Bocchia http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Gozzetti, Alessandro
Bacchiarri, Francesca
Sammartano, Vincenzo
Defina, Marzia
Sicuranza, Anna
Mecacci, Bianca
Zappone, Elisabetta
Cencini, Emanuele
Fabbri, Alberto
Raspadori, Donatella
Bocchia, Monica
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
title Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
title_full Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
title_fullStr Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
title_full_unstemmed Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
title_short Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
title_sort long-term safety of rapid daratumumab infusions in multiple myeloma patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783633/
https://www.ncbi.nlm.nih.gov/pubmed/33415072
http://dx.doi.org/10.3389/fonc.2020.570187
work_keys_str_mv AT gozzettialessandro longtermsafetyofrapiddaratumumabinfusionsinmultiplemyelomapatients
AT bacchiarrifrancesca longtermsafetyofrapiddaratumumabinfusionsinmultiplemyelomapatients
AT sammartanovincenzo longtermsafetyofrapiddaratumumabinfusionsinmultiplemyelomapatients
AT definamarzia longtermsafetyofrapiddaratumumabinfusionsinmultiplemyelomapatients
AT sicuranzaanna longtermsafetyofrapiddaratumumabinfusionsinmultiplemyelomapatients
AT mecaccibianca longtermsafetyofrapiddaratumumabinfusionsinmultiplemyelomapatients
AT zapponeelisabetta longtermsafetyofrapiddaratumumabinfusionsinmultiplemyelomapatients
AT cenciniemanuele longtermsafetyofrapiddaratumumabinfusionsinmultiplemyelomapatients
AT fabbrialberto longtermsafetyofrapiddaratumumabinfusionsinmultiplemyelomapatients
AT raspadoridonatella longtermsafetyofrapiddaratumumabinfusionsinmultiplemyelomapatients
AT bocchiamonica longtermsafetyofrapiddaratumumabinfusionsinmultiplemyelomapatients